Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404569 · ClinicalTrials.gov registry record · Phase 1
Continued Treatment for Participants Enrolled in Studies of BXQ-350
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04404569: Clinical Trial Phase 1 study, sponsored by Bexion Pharmaceuticals.
NCT04404569 is a Phase 1 study that was terminated before completion, run by Bexion Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404569, a Phase 1 study, was terminated before completion, sponsored by Bexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.
Primary Outcome
Subjects will be assessed at every visit for continued clinical benefit as per Investigator's assessment.
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
Why NCT04404569 stopped before completion
NCT04404569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT04404569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04404569 about?
NCT04404569 is a clinical study titled "Continued Treatment for Participants Enrolled in Studies of BXQ-350". This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment...
What is the current status of trial NCT04404569?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-06-08. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT04404569?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT04404569?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04404569's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI